Stock Events

Stock Events

Zevra Therapeutics 

$10.27
141
+$0.04+0.39%Thursday 20:00
+$0.00+0%Thursday 23:30After hours

Statistics

Day High
10.5
Day Low
10.24
52W High
15.04
52W Low
8.01
Volume
38,922
Avg. Volume
-
Mkt Cap
609.87M
P/E Ratio
6.64
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Nov 11Expected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.67
0.31
1.29
2.26
Expected EPS
0.157589
Actual EPS
N/A

Financials

78.17%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
106.47MRevenue
83.23MNet Income

Analyst Ratings

$27.14Average Price Target
The highest estimate is ⁦35.00⁩.
From 7 ratings within the last 6 months. This is not an investment recommendation.
Buy
86%
Hold
14%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ZVRA. It's not an investment recommendation.
Oscar Health
23
OSCR
Novo Nordisk
22
NVO
AST SpaceMobile
22
ASTS
Zeta Global
21
ZETA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap46.1B
Teva Pharmaceutical Industries is a global leader in generic and specialty medicines, competing in various therapeutic areas covered by Zevra Therapeutics.
Johnson & Johnson
JNJ
Mkt Cap617.01B
Johnson & Johnson operates in the pharmaceutical sector with a broad range of products that could compete with Zevra's offerings in pain management and CNS disorders.
Pfizer
PFE
Mkt Cap158.45B
Pfizer is a large pharmaceutical company with a diverse portfolio that includes treatments in areas potentially overlapping with Zevra Therapeutics' focus.
Novartis
NVS
Mkt Cap268B
Novartis is a global healthcare company that offers products in multiple segments, including those that could compete with Zevra Therapeutics in pain management and neurological conditions.
Abbvie
ABBV
Mkt Cap464.43B
AbbVie has a strong presence in the pharmaceutical market, including areas like CNS disorders, which could put it in direct competition with Zevra Therapeutics.
Merck
MRK
Mkt Cap356.01B
Merck & Co., Inc. is known for its innovative medicines and vaccines, some of which may compete with Zevra Therapeutics' products in the therapeutic areas they target.
Bristol-Myers Squibb
BMY
Mkt Cap124.91B
Bristol Myers Squibb has a diverse portfolio of prescription medicines, including those in areas that could compete with Zevra Therapeutics' focus areas.
Lilly(Eli) &
LLY
Mkt Cap1.02T
Eli Lilly and Company is a competitor due to its strong emphasis on neuroscience and pain management, areas that overlap with Zevra Therapeutics' interests.
GSK
GSK
Mkt Cap94.23B
GlaxoSmithKline plc has a broad range of pharmaceutical products, including those for pain management and CNS disorders, making it a competitor to Zevra Therapeutics.
Sanofi
SNY
Mkt Cap95.65B
Sanofi operates globally in the pharmaceutical sector, offering products that could compete with Zevra Therapeutics in several therapeutic areas.

About

Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.
Show More
CEO
Neil F. McFarlane
Employees
61
Country
United States
ISIN
US4884452065
WKN
000A2QLX7

Listings

F
DE
1GDA.F
STU
DE
1GDA.STU
MU
DE
1GDA.MU
XNAS
US
ZVRA

0 Comments

Share your thoughts

FAQs

What is Zevra Therapeutics stock price today?▼
The current price of ZVRA is $10.27 USD — it has increased by +0.39% in the past 24 hours. Watch Zevra Therapeutics stock price performance more closely on the chart.
What is Zevra Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Zevra Therapeutics stocks are traded under the ticker ZVRA.
Is Zevra Therapeutics stock price growing?▼
ZVRA stock has fallen by -9.83% compared to the previous week, the month change is a -12.97% fall, over the last year Zevra Therapeutics has showed a -9.75% decrease.
What is Zevra Therapeutics market cap?▼
Today Zevra Therapeutics has the market capitalization of 609.87M
When is the next Zevra Therapeutics earnings date?▼
Zevra Therapeutics is going to release the next earnings report on November 11, 2026.
What were Zevra Therapeutics earnings last quarter?▼
ZVRA earnings for the last quarter are 0.14 USD per share, whereas the estimation was 0.11 USD resulting in a +27.27% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Zevra Therapeutics revenue for the last year?▼
Zevra Therapeutics revenue for the last year amounts to 106.47M USD.
What is Zevra Therapeutics net income for the last year?▼
ZVRA net income for the last year is 83.23M USD.
How many employees does Zevra Therapeutics have?▼
As of October 16, 2026, the company has 61 employees.
In which sector is Zevra Therapeutics located?▼
Zevra Therapeutics operates in the Health & Wellness sector.
When did Zevra Therapeutics complete a stock split?▼
Zevra Therapeutics has not had any recent stock splits.
Where is Zevra Therapeutics headquartered?▼
Zevra Therapeutics is headquartered in BOSTON, United States.